NASDAQ: VCYT ยท Diagnostics & Research
Veracyte (VCYT) fair value and price range
As of 14 Nov 2026, Faircurve's model values Veracyte (VCYT) at $27.86 a share. The stock last closed at $24.01, which puts the model's fair value 16.0% above the price. The inputs behind this valuation are under review, so no verdict is shown.
- The company's market value changed by more than half within a week, so the financial statements behind this valuation describe the company before that change. No verdict is shown.
Revalued . Price is the close of 16 Nov 2026. Veracyte, Inc.
The report adds the live price, the chart against the range the options market prices and the next earnings date. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 held the fair value at $27.86, within 1% of the run of 7 Nov 2026.
What the model makes of itThe price of $24.01 is 16.0% below it. The inputs behind this valuation are under review, so no verdict is shown.
What's nextNext report on 24 Feb 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give VCYT?
The calibrated range for VCYT over 63 trading days is $19.82 to $29.36. It sits around the last close, and its width comes from the volatility that VCYT's own options imply (58% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $20.54 to $36.92. In 65% of the simulations the fair value came out above the price the model ran on.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does VCYT report earnings, and how has the stock reacted?
Veracyte's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 13.5% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. VCYT's 30 day implied volatility works out to about 16.8% over one month.
On 10 Nov 2026 VCYT moved 7.2% in one session, against the 2.8% a day that options had priced: 2.6 times the implied size.
How VCYT moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 15.7%.
| Report date | Two session move |
|---|---|
| 4 Nov 2026 | -52.3% |
| 3 Nov 2026 | +7.2% |
| 30 Jul 2026 | -16.9% |
| 5 May 2026 | +23.1% |
| 25 Feb 2026 | +8.6% |
| 4 Nov 2025 | +26.3% |
| 6 Aug 2025 | +10.7% |
| 24 Feb 2025 | -14.6% |
How does VCYT score on business quality?
Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 73 | 7.0%ROIC | -9.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 83 | 1.27xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 78 | 16.0%Revenue growth, trailing | 6.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | not shown | Net buybacks / market value: not shown | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -1.20xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 30 | 12.0 ptsEBITDA margin downside volatility, 5y | 11.4 pts |
The company's market value halved or doubled within a week. The price is from after that change and the financial statements and estimates on file are from before it, so no multiple of the two and no estimate is shown.
How does VCYT compare with similar companies?
The companies in diagnostics & research closest to Veracyte in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| NEO NeoGenomics, Inc. | $15.41 | $15.88 | +3.0% | Fairly valued |
| SHC Sotera Health Company | $16.25 | $22.46 | +38.2% | Undervalued |
| RDNT RadNet, Inc. | $76.89 | $72.24 | -6.0% | Fairly valued |
| CRL Charles River Laboratories International, Inc. | $335.52 | $423.73 | +26.3% | Undervalued |
| RVTY Revvity, Inc. | $148.85 | $185.05 | +24.3% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
All diagnostics & research stocks ranked by gap to fair value
Veracyte at a glance
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
- Market value
- $2.0B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Analysts with estimates
- 5
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Veracyte on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for VCYT was $27.66. As of 14 Nov 2026 it is $27.86, a change of +0.7%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Veracyte's valuation
Is Veracyte stock undervalued or overvalued?
Faircurve's model puts VCYT's fair value at $27.86 a share against a last close of $24.01, as of 14 Nov 2026. The inputs behind this valuation are under review, so no verdict is shown.
What is VCYT's fair value?
$27.86 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $20.54 to $36.92.
What price range does the model give VCYT?
$19.82 to $29.36 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Veracyte report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has VCYT moved on past earnings reports?
Across its last 8 reports the median two session move was 15.7%, ignoring direction. The largest was -52.3% around the report of 4 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for VCYT is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.